Osteoarthritis (OA) is estimated to affect approximately 27 million adults in the United States, with a predisposition to degeneration of the hip and knee joint.[@bib1] With some estimates predicting the lifetime risk of OA development in the hip to be 25%, early management is imperative to reduce the burden of disease.[@bib2] The clinical manifestations of OA include chronic pain, inflammation, bone spurs, and decreased joint range of motion, all of which can greatly diminish quality of life[@bib3]; the radiographic evidence of OA is seen as osteophyte formation and joint space narrowing on radiographs.

One factor that increases the risk of OA progression is the presence of a subchondral bone marrow lesion (BML).[@bib4] BMLs have been shown to increase the incidence of OA by a factor of 2.5.[@bib5] These BMLs are defined as localized edema within the subchondral bone, which can be due to early chondromalacia changes, subchondral insufficiency stress or microfractures, and sometimes avascular necrosis. The lesions are visualized as regions of hyperintensity on fat-suppressed T2-weighted magnetic resonance imaging (MRI) sequences.[@bib6]^,^[@bib7] Plain radiographic imaging of patients with BMLs will often show femoroacetabular impingement (FAI), which can complicate surgical management if a delamination injury to the acetabular articular cartilage is present.[@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13] Gdalevitch et al.[@bib14] showed that radiographic visualization of delamination cysts---caused by leakage of intra-articular joint fluid into subchondral bone due to microfractures caused by delamination of articular cartilage---in the anterosuperior part of the acetabulum could predict delamination of the acetabular articular cartilage adjacent to labral tears with 80% sensitivity and 96.3% specificity.

Treatment for OA ranges from nonsurgical measures, such as oral analgesics and physical therapy, to surgical treatment, such as hip or knee arthroplasty.[@bib15] Although arthroplasty is the definitive treatment for moderate to severe OA, the procedure comes with potential risks[@bib16] and resulting activity restrictions.[@bib17] Many patients, particularly those who are younger and more active, prefer a less invasive procedure that may preserve natural joint function and offer an option for hip preservation. In recent years, Subchondroplasty (SCP) has emerged as a promising early intervention alternative to arthroplasty in the setting of a BML with no significant degenerative changes in the hip.

SCP, a technique developed in the knee in 2007, involves image- and/or arthroscopic-guided injection of calcium phosphate into the BML.[@bib18] This technique has been shown to be efficacious in several clinical trials in which the calcium phosphate was injected into BMLs within the distal femur and/or proximal tibia.[@bib6]^,^[@bib19], [@bib20], [@bib21], [@bib22] The clinical outcomes of SCP of the hip have been less studied. This Technical Note will outline the procedural steps to perform SCP of the hip. In addition, various clinical trials on SCP will be discussed, including an ongoing trial related to the hip.

Technique {#sec1}
=========

Preoperative Steps {#sec1.1}
------------------

The BML should be localized and characterized using fat-saturated T2-weighted MRI ([Fig 1](#fig1){ref-type="fig"}). Lesions will appear as areas of hyperintensity on this sequence. Clinical and radiographic correlations are important to define these lesions. All concomitant pathology, such as an acetabular labral tear and zones of FAI ([Fig 2](#fig2){ref-type="fig"}), should be defined and addressed at the time of surgery. Without treatment of coexisting pathology (e.g. FAI), the ultimate success of SCP for BML treatment may be compromised. Presurgical planning involves identifying the paths of the SCP instruments needed to accurately penetrate the areas of the BML. This will be correlated with intraoperative imaging (e.g. fluoroscopy) and arthroscopic landmarks and findings.Fig 1Visualization of a bone marrow lesion in the coronal plane using fat-suppressed T2-weighted magnetic resonance imaging. Lesions are indicated with arrows and appear as areas of hyperintensity. (Reprinted with permission from Zimmer Biomet.)Fig 2Simulated impingement zones in combined cam-pincer scenario (white and black arrows). The location and treatment of any concomitant pathology, such as zones of femoroacetabular impingement, should be addressed at the time of Subchondroplasty to maximize the results of the Subchondroplasty procedure.

Zonal Anatomy {#sec1.2}
-------------

[Figure 3](#fig3){ref-type="fig"} illustrates the anatomic zones within which BMLs are codified. Acetabular BMLs most often occur in areas of impingement (zone 2), areas of maximal weight bearing (zone 3L), and areas with superior retroversion (zones 1 and 2). When a BML is found in zone 4, it is usually as a late finding of OA. Femoral BMLs occur in areas of weight bearing (zones 2 and 3L) and parafoveal areas (zone 3M).[@bib23]Fig 3Zonal anatomy of acetabulum and femoral head. Acetabular bone marrow lesions (BMLs) commonly occur in zones 1, 2, 3L, and 4. Femoral BMLs commonly occur in zones 2, 3L, and 3M. Common areas of impingement include zone 2 (acetabulum), areas of maximal weight bearing include zone 3L (acetabulum and femoral head) and zone 2 (femoral head), and areas of superior retroversion include zones 1 and 2 (acetabulum). BMLs found within zone 4 are a common late finding of osteoarthritis. (Ant, anterior; Dist, distal; Inf, inferior; Lat, lateral; Med, medial; Post, posterior; Prox, proximal; Sup, superior.)

Intraoperative Steps for Femoral Head BML {#sec1.3}
-----------------------------------------

The patient is placed in the supine position on a radiolucent table with the fluoroscopy unit coming in from the contralateral side of the table ([Fig 4](#fig4){ref-type="fig"}). The table should accommodate hip arthroscopy (e.g. Hana table, Mizuho OSI, Union City, CA) owing to concomitant treatment in the central and peripheral hip compartments and to address any intra-articular pathology. Hip arthroscopy access also allows for any removal of intra-articular extravasation of the hydrophilic injectate.Fig 4Placement of the patient in a supine position on a radiolucent table compatible with hip arthroscopy; the fluoroscopy unit comes from the contralateral side (black arrow). Using a table compatible with arthroscopy allows for treatment of intra-articular pathologies and removal of extravasated material. The Subchondroplasty access site is shown by the white arrow. (Reprinted with permission from Zimmer Biomet.)

The operative leg is internally rotated, and the lesser trochanter--neck-shaft angle is marked ([Fig 5](#fig5){ref-type="fig"}). After a skin incision is made, a wire driver should be used to assist in placement of the AccuPort trocar-cannula system (Zimmer Knee Creations Incorporated, Exton, PA) through the lateral femoral cortex above the level of the lesser trochanter ([Video 1](#appsec1){ref-type="sec"}). Keeping the entry point above the level of the lesser trochanter decreases the chance of a proximal femoral fracture. The trocar-cannula system has a length of 200 mm and diameter of 4.2 mm (8 gauge) and is able to support side-delivery, end-delivery, multi-delivery, and zone-delivery configurations ([Fig 6](#fig6){ref-type="fig"}). The trocar is advanced up through the intertrochanteric region into the femoral neck. Proper placement of the cannula can be confirmed with fluoroscopy in multiple projections ([Fig 7](#fig7){ref-type="fig"}); we suggest keeping the fluoroscopy machine stationary and having the assistant perform frog-leg lateral positioning of the leg ([Fig 8](#fig8){ref-type="fig"}) to obtain the lateral view of the neck. It is important to assess the planned trajectory after the cannula has been advanced only to the intertrochanteric line ([Fig 9](#fig9){ref-type="fig"}); if a new trajectory is deemed necessary, the cannula can be withdrawn to the cortex and then redirected without creating undue stress in the femoral neck. Subsequent adjustments can be made by backing the cannula out and redirecting under fluoroscopic guidance if needed; redirection should not be attempted when the cannula is embedded in bone. It is best to perform any redirections prior to the tip of the trocar passing beyond the head-neck junction of the proximal femur to avoid any stress risers in the femoral neck. Future instrumentation will accommodate a guidewire for targeting the lesion, prior to drilling ([Fig 10](#fig10){ref-type="fig"}). An alternate technique is to access femoral head lesions through an arthroscopic cannula and under arthroscopic visualization, but care should be taken to avoid penetrating the femoral head zones of the articular cartilage.Fig 5Internal rotation of the operative leg with marking of the lesser trochanter--neck-shaft angle with the patient in the supine position. All portal entry points are kept above the level of the lesser trochanter to reduce the possibility of a proximal femoral fracture. Anteroposterior fluoroscopic views are used to visualize the lesser trochanter and neck-shaft angle. A wire driver is used to assist in placement of the trocar-cannula system. (Reprinted with permission from Zimmer Biomet.)Fig 6Trocar-cannula system with end-delivery, side-delivery, multi-delivery, and zone-delivery configurations. The trocar-cannula system has a length of 200 mm and diameter of 4.2 mm (8 gauge), allowing ample space for injection of AccuFill Bone Substitute Material (BSM). Approximately 3 mL of AccuFill BSM will be injected into the bone marrow lesion. (Reprinted with permission from Zimmer Biomet.)Fig 7Advancement of the trocar into the femoral neck via the intertrochanteric region using multiple anteroposterior fluoroscopic projections to help with guidance. The bone marrow lesion is visualized as labeled hyperintensity. The patient is kept in the frog-leg lateral position during fluoroscopic projections. (Reprinted with permission from Zimmer Biomet.)Fig 8Visualization of a lateral projection of the femoral neck with the patient\'s leg placed in the frog-leg lateral position. The fluoroscopy machine is held stationary while an assistant places the patient in the correct frog-leg lateral position, thereby allowing for optimal visualization of lesions.Fig 9Assessment of the cannula trajectory at the intertrochanteric line using an anteroposterior fluoroscopic view. This assessment allows the surgeon to make adjustments to the planned trajectory by withdrawing to the cortex. Any redirections should be performed before passing the head-neck junction of the femur to prevent any unnecessary stress on the femoral neck. Redirection should not occur if the cannula is embedded in bone. (Reprinted with permission from Zimmer Biomet.)Fig 10Future cannula design with guidewire (arrow), which will allow the surgeon to target the lesion prior to drilling, thereby reducing the number of steps required to inject AccuFill Bone Subsitute Material within a bone marrow lesion. (Reprinted with permission from Zimmer Biomet.)

For a typical femoral head BML, an 8-gauge AccuPort cannula is usually used. Once the cannula has entered the femoral head BML, the stylus should be removed from the cannula by gently reversing the wire driver. To remove any excess heat generated from drilling, 2 mL of saline solution can be injected or the surgeon can wait 2 minutes before proceeding with injection of the calcium phosphate. Performing the calcium phosphate material injection (AccuFill Bone Substitute Material (BSM), Zimmer Knee Creations Incorporated, Exton, PA) prior to any osteochondroplasty (e.g. addressing a cam lesion) is recommended so that the material is "contained" until it completely hardens.

At this point, the AccuFill BSM can be injected. The cannula volume itself is 1 to 2 mL. Generally, 3 to 5 mL of AccuFill BSM is used for a typical femoral lesion. A small test dose can be injected prior to full-volume injection to assess for unwanted extravasation. Verification of proper location, as well as lack of extravasation, can be made with fluoroscopic and/or arthroscopic guidance. Once the material has been fully injected, the AccuFill BSM is allowed to harden over a period of 8 to 10 minutes. The trocar stylus is then reconnected to the cannula, and the cannula is removed. Because of the small-diameter hole of the trocar-cannula system, backfilling of the cannula tract is not required.

Intraoperative Steps for Acetabular BML {#sec1.4}
---------------------------------------

On the basis of the location of the BML, the lesion may be accessed through percutaneous incisions or via an arthroscopic cannula ([Fig 11](#fig11){ref-type="fig"}). The standard hip arthroscopic portals should be placed at the surgeon\'s preference, and an accessory portal may be used for the SCP cannula insertion. For an acetabular BML, a 11-gauge AccuPort cannula is usually used. The cannula is advanced to the BML; generally, the tip of the cannula is within several millimeters of the subchondral plate. Fluoroscopy may be used for visualization, in conjunction with arthroscopic visualization and guidance as needed. Once the cannula is placed in the desired location, the stylus should be removed from the cannula by gently reversing the wire driver. Next, approximately 3 mL of AccuFill BSM is injected (it should be noted that the volume of the cannula is about 1 mL) for a typical lesion. After appropriate hardening time of the injectate, the stylus can be reconnected to the cannula, and the apparatus can be removed. It is recommended to perform the AccuFill BSM injection prior to any bony acetabular work (e.g. addressing a pincer lesion) and placement of anchors so that the material is contained until it completely hardens. Furthermore, the AccuFill BSM may offer additional cancellous bone support in the revision hip arthroscopy setting when placing anchors in compromised bone.Fig 11Access to bone marrow lesion using arthroscopic cannula. Standard hip arthroscopic portals (arrows) are used (i.e. anterolateral placed first, anterior placed second, and posterolateral placed third). Both the portals and cannula are accessed from the lateral aspect of the patient. An arthroscope is placed within the anterolateral port using a guidewire. (Reprinted with permission from Zimmer Biomet.)

AccuFill Material {#sec1.5}
-----------------

AccuFill BSM, which has an average total crystal volume of 1,664 nm^3^, is similar to native bone mineral, which has an average total crystal volume of 1,485 nm^3^. This crystalline structure, along with flowability, allows AccuFill BSM to flow into intact spongy bone and to be broken down by osteoclasts as native bone apatite. AccuFill BSM is also highly macroporous, allowing for increased surface area for cellular activity. Other parallels to native bone include a similar compressive strength (approximately 7-9 MPa). Isothermic hardening of AccuFill BSM ensures that tissue necrosis does not occur when injected into spongy bone and allows for concomitant use with bone marrow concentrate (e.g. in the setting of core decompression for avascular necrosis). If the hydrophilic AccuFill BSM enters the joint space ([Fig 12](#fig12){ref-type="fig"}), it can be removed with an arthroscopic shaver device. A summary of AccuFill BSM properties is presented in [Table 1](#tbl1){ref-type="table"}, and a comparison to other commercially available products is shown in [Table 2](#tbl2){ref-type="table"}. Pearls and pitfalls of the SCP procedure are shown in [Table 3](#tbl3){ref-type="table"}, and advantages and disadvantages are presented in [Table 4](#tbl4){ref-type="table"}.Fig 12Removal of extravasated AccuFill Bone Substitute Material (BSM) from the joint space using an arthroscopic shaver device. Approximately 3 mL of AccuFill BSM is injected into a bone marrow lesion. The hydrophilic nature of the AccuFill BSM allows it to be easily removed with the arthroscopic shaver device. The arthroscope is inserted from the anterolateral portal. (Reprinted with permission from Zimmer Biomet.)Table 1AccuFill Bone Substitute Material (BSM) Material DataMaterialAverage Nanocrystal Length, nmAverage Nanocrystal Width, nmAverage Nanocrystal Height, nmTotal\
Volume, nm[@bib3]Human bone mineral23-326.7-8.06.7-8.01,485AccuFill BSM26881,664[^1]Table 2Comparison of Material Data for AccuFill BSM and Other Commercially Available ProductsMaterial And/or Brand Name if AvailableCompanyChemical FormulaHuman bone mineralNACa~10-x~(M)~x~(PO~4~)~6-x~(HPO~4~,CO~3~)~x~(OH)~2-x~AccuFill Bone Substitute MaterialETEX Corporation (Cambridge, MA)Ca~10-x~(M)~x~(PO~4~)~6-x~(HPO~4~,CO~3~)~x~(OH)~2-x~Norian Skeletal Repair SystemSynthes (West Chester, PA)Ca~10-x~(PO~4~)~6-x~(HPO~4~,CO~3~)~x~(OH)~2-x~BoneSourceStryker Corporation (Kalamazoo, MI)Ca~10-x~(PO~4~)~6-x~(HPO~4~)~x~(OH)~2-x~Vitoss (β-TCP)Stryker Corporation (Kalamazoo, MI)Ca~3~(PO~4~)~2~ActifuseBaxter International Incorporated (Deerfield, IL)Ca~10~(PO~4~)~6-x~(SiO~4~)~x~(OH)~2-x~[^2][^3]Table 3Summary of Pearls and Pitfalls of SubchondroplastyPearlsPitfallsVisualization of BML is performed using fat-saturated T2-weighted MRI.Care should be taken not to extravasate injected material into the surrounding soft-tissue structures.Intraoperative fluoroscopy can help guide the cannula.Concomitant pathologies (i.e. acetabular labral tear and FAI) should be addressed at the time of surgery.BML can be accessed via a percutaneous incision or arthroscopic cannula.The entry point of the cannula system should be kept above the level of the lesser trochanter to reduce the likelihood of a proximal femoral fracture.The cannula should not be redirected if directly embedded in bone; rather, the cannula should be backed out and redirected using fluoroscopy to reduce stress on the femoral neck.[^4]Table 4Summary of Advantages and Disadvantages of SubchondroplastyAdvantages Subchondroplasty is minimally invasive, with improvement in pain scores in most patients Can help delay onset of invasive procedures such as total hip arthroplasty Preservation of natural joint functionDisadvantages Lack of familiarity with surgical technique requiring additional training Lack of efficacy in certain patients Postoperative pain

Discussion {#sec2}
==========

BMLs have been shown to increase the risk of OA.[@bib3] It has previously been shown that BMLs often occur at low-cartilage and high-stress areas within the acetabulum and can irritate the numerous nerve fibers that are present in bone marrow.[@bib24]^,^[@bib25] Imaging of patients with BMLs will often show concomitant labral tears and FAI. Although BMLs can also be seen on radiographs, fat-suppressed MRI sequences are used to confirm findings.[@bib6]

Risk factors for BMLs include hip impingement, developmental dysplasia of the hip, chondromalacia, insufficiency injuries and stress responses, obesity, and avascular necrosis. These factors lead to numerous micro-insufficiency fractures within the bone.[@bib26] As a result, bone trabeculae are decreased, which causes a reduction in the elastic resistance of bone and numerous microtrabecular fractures. This leads to increased pressure and edema within the bone. As a result of Wolff\'s law, the bone will respond to the increased pressure by greatly increasing subchondral bone turnover and angiogenesis.[@bib27] The pain associated with BMLs is due to the associated increased vascularity and innervation of bone marrow; lesions that are closer to the subchondral plate will elicit more pain due to the presence of numerous nerve endings.[@bib28] Furthermore, BMLs have been shown to be an independent risk factor that leads to worse outcomes on metrics such as the Hip Outcome Score after hip arthroplasty[@bib29]; therefore, our understanding of early processes that stimulate BMLs may affect patient satisfaction.

The most common locations of BMLs are the knee and hip. Knee BMLs occur at high-stress areas such as the medial tibial plateau and medial femoral condyle. Hip BMLs mainly occur in the acetabulum, although femoral head BMLs are routinely seen.[@bib23] The propensity for acetabular BMLs may be due to the concave surface, properties of the subchondral plate, and other factors as shown in finite element analysis.[@bib24]

Subchondroplasty offers a minimally invasive surgical option that has shown promise in alleviating pain and exacerbation of OA in patients with BMLs. Since 2013, there have been 5 main clinical trials that have assessed the use of SCP for BMLs within the knee ([Table 5](#tbl5){ref-type="table"}). Most of the clinical trials involving knee SCP have revealed positive results. The largest of these trials, conducted by Cohen and Sharkey,[@bib22] showed that 88% of patients (50 of 57) reported positive improvements in pain scores 6 months after receiving subchondroplasty. Similarly, Bonadio et al*.*[@bib6] and Farr and Cohen[@bib19] showed improvements in pain metrics such as the visual analog scale score, as well as the Knee Injury and Osteoarthritis Outcome Score, International Knee Documentation Committee score, and 12-item Short Form Health Survey score. Yoo et al.[@bib21] reported that patients who first received SCP and then later underwent total or unicompartmental knee arthroplasty showed no difference in outcomes compared with patients who underwent arthroplasty alone, suggesting that SCP may not compromise the results of subsequent arthroplasty treatment. It is worth mentioning that of the 22 patients in the trial of Chatterjee et al.,[@bib20] 7 reported poor outcomes and 3 reported fair outcomes per the Tegner knee scoring scale; the authors considered these cases to be clinical failures. Unlike other studies, the patients in this trial all had moderate to severe OA, suggesting that SCP is less successful in moderate to severe OA. In our practice, we do not perform SCP in the setting of advanced arthritis.Table 5Summary of Key Clinical Trials Involving Subchondroplasty for Management of Knee Bone Marrow LesionsAuthors (Year)No. of Patients Who Underwent SubchondroplastyInclusion CriteriaExclusion CriteriaResultsCohen and Sharkey[@bib22] (2016)66Presence of BML in tibia or femur\
Moderate or severe pain for \>2 mo\
Failure of symptom improvement from conservative treatment (i.e. NSAIDs and/or corticosteroids)Severe malalignment (\>8° of varus-valgus)\
Severe grade IV OA (per Kellgren-Lawrence grading)\
Pain from cause outside of BMLOf 57 patients with preoperative and postoperative VAS scores, 50 had improvement in symptoms, 4 had no change, and 3 had worsening pain. The mean change in the VAS score was 4.3 after 6 mo and 4.5 after 2 yr of follow up (score \>2 considered relevant).\
Of 48 patients with preoperative and postoperative IKDC scores, 38 had improvement in symptoms, 1 had no change, and 9 had worse pain. The mean change in the IKDC score was 17.2 after 6 mo and 17.8 after 2 yr (score \>11.5 considered relevant).Bonadio et al.[@bib6] (2017)5Knee pain for \>6 mo\
Presence of BML confirmed by MRIModerate grade III OA (per Kellgren-Lawrence grading)\
Severe malalignment (\>8° of varus-valgus)\
Alterations of patellofemoral joint (per radiography)\
Autoimmune and/or renal diseaseMean change in KOOS: 24.6 (1 wk postop), 19.64 (3 wk postop), 19.48 (6 wk postop), 24.9 (12 wk postop), and 32.82 (24 wk postop)\
Mean change in VAS score: --5 (1 wk postop), --4.8 (3 wk postop), --5 (6 wk postop), --6 (12 wk postop), and --7.2 (24 wk postop)Yoo et al.[@bib21] (2016)22 (all of whom eventually underwent TKA or UKA)Moderate to severe grade III-IV OA (per Kellgren-Lawrence grading)\
Presence of BML confirmed by MRI\
Failure of symptom improvement from conservative treatment (i.e. NSAIDs and/or corticosteroids)Not listedMean OKS: 40.6 compared with 40.1 for patients undergoing only TKA or UKA without prior subchondroplasty (insignificant difference, *P* = .66)\
No major complications in patients who underwent future TKA or UKA after subchondroplastyFarr and Cohen[@bib19] (2013)59Prior knee pain\
Presence of BML confirmed by MRINot listedTKA or UKA was performed in 15 patients because of unresolved pain.\
Among patients who did not undergo further surgery, the mean change in the VAS pain score at 6 mo postop was --4.4, the mean change in the IKDC score at 6 mo postop was 22.4, and mean change in the SF-12 score at 6 mo postop was 6.9.Chatterjee et al.[@bib20] (2015)33 (22 of whom met appropriate inclusion and exclusion criteria and were available for 6-mo follow-up)Presence of BML confirmed by MRI\
Failure of symptom improvement from conservative treatment (i.e. NSAIDs and/or corticosteroids)\
Moderate to severe grade III-IV OA (per Kellgren-Lawrence grading)Severe malalignment (\>8° of varus-valgus)\
Nondegenerative meniscal tear near BML lesion\
Fracture and/or dislocationThe mean change in the KOOS at 6 mo postop was 31.8.\
The mean change in the Tegner-Lysholm score at 6 mo postop was 29.5.\
Further analysis of Tegner-Lysholm scores revealed that 7 patients had excellent results, 5 had good results, 3 had fair results, and 22 had poor results.[^5]

Although SCP is generally tolerated, the procedure is not without risk. In 1 case report, a 64-year-old male patient who received SCP to treat a BML of the medial femoral condyle contracted *Staphylococcus aureus* osteomyelitis.[@bib30] The patient had reported positive improvement in pain management, although purulent drainage eventually developed, which was ultimately treated with antibiotics and surgical irrigation and debridement. Given the very small sample size of the study, it is likely that the infection arose due to suboptimal sterile technique. This should be contrasted with the results of Farr and Cohen,[@bib19] who found that no infections developed in a sample of 59 patients who underwent SCP ([Table 5](#tbl5){ref-type="table"}). Some short-term technical challenges that are seen with SCP include extravasation or leakage of calcium phosphate within surrounding soft-tissue structures, postoperative leakage of calcium phosphate, and postoperative pain.[@bib19]^,^[@bib31] Long-term technical challenges with subchondroplasty appear to be minimal, given that Yoo et al.[@bib21] showed that patients who received prior subchondroplasty injections who later underwent arthroplasty did not differ from patients without SCP in terms of operative time, blood loss, or surgical revisions.

The first major clinical trial assessing SCP of the hip is currently underway and is industry funded.[@bib32] In total, 100 patients will be enrolled based on the following criteria: BML, insufficiency fracture, or avascular necrosis of the femur and/or acetabulum. The study is expected to enroll patients until March 2022. It is planned for patients to report outcomes such as pain, activity level, and overall satisfaction up to several years postoperatively. This study may offer insight into the short- and mid-term durability of SCP in the hip, as well as for those patients whom this technique may offer an alternative for early intervention.

Hip SCP is an emerging surgical technique in which a calcium phosphate material is injected into BMLs. As the primary generator of pain, the subchondral bone and associated microfractures associated with increased stress concentrations may offer a surgical target for helping with symptomatic hip pain in patients with preserved overall hip cartilage. A similar procedure and technique have shown promising results in the treatment of BMLs of the knee. A longitudinal cohort study of hip SCP is currently recruiting patients for enrollment. Further study in broader patient populations will help to define the role of SCP in the hip. Furthermore, future work should characterize the utility of SCP for the management of hip pathology and whether this is a durable alternative to OA in patients with BML, focal correctable anatomic issues, and minimal femoroacetabular degenerative changes.

Supplementary Data {#appsec1}
==================

Video 1Subchondroplasty hip technique: intraoperative cannula placement and delivery for femoral and acetabular lesions.ICMJE author disclosure forms
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[^1]: NOTE. Reprinted with permission from Zimmer Biomet.

[^2]: NOTE. Reprinted with permission from Zimmer Biomet.

[^3]: NA, not applicable; TCP, tricalcium phosphate.

[^4]: BML, bone marrow lesion; FAI, femoroacetabular impingement; MRI, magnetic resonance imaging.

[^5]: BML, bone marrow lesion; IKDC, International Knee Documentation Committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs; OA, osteoarthritis; OKS, Oxford Knee Score; postop, postoperatively; SF-12, 12-item Short Form Health Survey; TKA, total knee arthroplasty; UKA, unicompartmental knee arthroplasty; VAS, visual analog scale.
